Multilamellar Vaccine Particle Elicits Potent Immune Activation with Protein Antigens and Protects Mice against Ebola Virus Infection

作者：Yuchen Fan, Sabrina M. Stronsky, Yao Xu, Jesse Steffens, Sean A. Van Tongeren, Amanda L. Erwin, Christopher L. Cooper, James J. Moon · 发表于：ACS Nano · 年份：2019 · DOI：10.1021/acsnano.9b03660 · 被引用次数：41 · 研究领域：Viral Infections and Outbreaks Research、SARS-CoV-2 and COVID-19 Research、COVID-19 epidemiological studies

Recent outbreaks of emerging infectious diseases, such as Ebola virus disease (EVD), highlight the urgent need to develop effective countermeasures, including prophylactic vaccines. Subunit proteins derived from pathogens provide a safe source of antigens for vaccination, but they are often limited by their low immunogenicity. We have developed a multilamellar vaccine particle (MVP) system composed of lipid–hyaluronic acid multi-cross-linked hybrid nanoparticles for vaccination with protein antigens and demonstrate their efficacy against Ebola virus (EBOV) exposure. MVPs efficiently accumulated in dendritic cells and promote antigen processing. Mice immunized with MVPs elicited robust and long-lasting antigen-specific CD8 + and CD4 + T cell immune responses as well as humoral immunity. A single-dose vaccination with MVPs delivering EBOV glycoprotein achieved an 80% protection rate against lethal EBOV infection. These results suggest that MVPs offer a promising platform for improving recombinant protein-based vaccine approaches.